On August 13, 2026, Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application and issued a "Study May Proceed" letter for the Phase 3 clinical trial of denifanstat in moderate to severe acne. This regulatory milestone allows the company to initiate pivotal testing for its fatty acid synthase inhibitor candidate. Sagimet Biosciences Inc. operates in the biotechnology industry, focusing on the development of small molecule therapeutics.

Sagimet Biosciences Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $14.0 million compared to $10.4 million in the prior year period. The company held $257.6 million in cash and marketable securities as of June 30, 2026, which management expects will fund operations through 2028, including data readout from its Phase 3 denifanstat trial. Sagimet announced plans to initiate a registrational Phase 3 clinical trial for denifanstat in moderate to severe acne patients in the United States during the second half of 2026. Additionally, the company confirmed that its first-in-human Phase 1 trial for the FASN inhibitor TVB-3567 is ongoing and aims to begin a Phase 2 acne trial before the end of 2026. Sagimet Biosciences Inc. operates in the clinical-stage biopharmaceutical industry, developing novel fatty acid synthase inhibitors for metabolic and dermatological diseases.

Sagimet Biosciences Inc. updated its investor presentation on July 20, 2026, highlighting clinical progress for its lead molecule, denifanstat. The company reported that denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for moderate to severe acne in China, where the NDA was accepted by the NMPA in December 2025. Sagimet plans to initiate a US-based Phase 3 clinical trial for denifanstat in the second half of 2026. Additionally, the company's follow-on FASN inhibitor, TVB-3567, began a Phase 1 clinical trial in June 2025. As of March 31, 2026, the company held $104.5 million in cash. Sagimet is a biotechnology company developing novel therapeutics for metabolic and dermatological diseases.